scholarly journals Skull base meningiomas: development of treatment methods

2021 ◽  
Vol 23 (3) ◽  
pp. 93-103
Author(s):  
S. E. Zuev ◽  
A. S. Tokarev
Keyword(s):  
Targeted Therapy ◽  
Surgical Treatment ◽  
Skull Base ◽  
Proton Therapy ◽  
Robotic Systems ◽  
Treatment Methods ◽  
Significant Events ◽  
Skull Base Meningiomas

The review describes the treatment methods for skull base meningiomas and promising modern trends in this area. The most significant events in the development of meningiomas’ surgical treatment are described. The current research and scientific approaches to the skull base meningiomas’ treatment are presented: medical robotic systems, targeted therapy, radiosurgery, and proton therapy.

Surgical Treatment of Skull Base Meningiomas: Risk Factors and Strategy of Treatment

Skull Base ◽  
2007 ◽  
Vol 16 (S 1) ◽  
Author(s):  
Yuri Aimi ◽  
Kiyoshi Saito ◽  
Takeshi Okada ◽  
Masahiro Ichikawa ◽  
Tetsuya Nagatani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Surgical Treatment ◽  
Skull Base ◽  
Skull Base Meningiomas

Lower doses to hippocampi and other brain structures for skull-base meningiomas with intensity modulated proton therapy compared to photon therapy

2020 ◽  
Vol 142 ◽  
pp. 147-153
Author(s):  
Mireille A. Florijn ◽  
Abdul Wahab M. Sharfo ◽  
Ruud G.J. Wiggenraad ◽  
Jan P.C. van Santvoort ◽  
Anna L. Petoukhova ◽  
...  
Keyword(s):  
Skull Base ◽  
Proton Therapy ◽  
Brain Structures ◽  
Intensity Modulated Proton Therapy ◽  
Intensity Modulated ◽  
Skull Base Meningiomas

scholarly journals The role of a multidisciplinary approach in the treatment of hepatocellular carcinoma

2020 ◽  
Vol 21 (4) ◽  
pp. 10-14
Author(s):  
Oleg I. Kit ◽  
Liubov Iu. Vladimirova ◽  
Anna E. Storozhakova ◽  
Tatiana A. Snezhko ◽  
Elena A. Kalabanova ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Targeted Therapy ◽  
Surgical Treatment ◽  
Viral Hepatitis ◽  
Multidisciplinary Approach ◽  
Local Treatment ◽  
Treatment Methods ◽  
Viral Hepatitis C ◽  
Advanced Stages

Aim. Evaluation of treatment options and efficacy in patients with hepatocellular carcinoma based on data from the FSBI Rostov Cancer Research Institute using a multidisciplinary approach to the problem. Materials and methods. 124 cases of hepatocellular carcinoma were analyzed. In 79.8% of patients (average age of 61.4 years) the disease was diagnosed at advanced stages (IIIIV). Antibodies to viral hepatitis B were detected in 18 (14.5%) patients, and antibodies to viral hepatitis C in 35 (28.2%) patients. Liver cirrhosis occurred in 38 (30.6%) cases, and ChildPugh class A in 20 (16.1%) cases. In the FSBI RCRI, a multidisciplinary approach has been introduced into clinical practice; decision on treatment tactics is made with a close cooperation of several specialists. The use of special treatment methods was available in 67 (54%) patients. 32 patients with Barcelona Clinic Liver Cancer (BCLC) stage A (early) or stage B (intermediate), had surgical treatment or hepatic arterial chemoembolization (HACE) with lipiodol or microspheres using various cytostatics (18 and 14 patients, respectively). 35 patients with advanced stage C were given a systemic therapy with various cytostatics (gemcitabine, oxaliplatin, doxorubicin) or targeted therapy with sorafenib. The treatment efficacy was assessed according to mRECIST. Results. The best median overall survival (OS) up to 21 months was in the group of patients (n=18) who underwent volume resection surgery. In this group, sorafenib was prescribed to 2 patients after surgery. When performing HACE, the median OS was 14.2 months. In 6 patients, HACE was performed 2 or more times. Among the 14 patients who had HACE, sorafenib was prescribed in 8 cases, and the median OS in this group was 16.3 months. 20 patients were given targeted therapy with sorafenib. Following 3 months of taking the drug, 16 patients achieved stabilization of the disease according to the mRECIST, in 1 patient a partial response, in 3 patients disease progression. Median OS was 9.1 months; progression-free survival among patients treated with sorafenib was 5.4 months. Conclusions. The use of a multidisciplinary approach in clinical practice makes it possible to choose the optimal treatment option for hepatocellular carcinoma and contributes to the improvement in OS. The combination of local treatment methods (surgical treatment, HACE) with effective drug therapy is the most optimal approach to treating patients with advanced stages of hepatocellular carcinoma.

scholarly journals Clinical results of basal meningiomas laser surgery

2008 ◽  
Vol 7 (5-2) ◽  
pp. 399-402
Author(s):  
V. V. Stupak ◽  
A. V. Kalinovsky ◽  
S. V. Maiorov ◽  
S. G. Struts
Keyword(s):  
Laser Radiation ◽  
Surgical Treatment ◽  
Skull Base ◽  
Laser Surgery ◽  
Clinical Results ◽  
Laser Application ◽  
Yag Laser ◽  
Skull Base Meningioma ◽  
Surgical Methods ◽  
Skull Base Meningiomas

Methods of surgical treatment of patients with skull base meningiomas using high intensity infrared laser radiation (ND-YAG laser) at a wavelength of 1.06 micron were developed. The paper presents results of Nd-YAG laser application in skull base meningioma removal with assessment of its efficacy as compared with conventional surgical methods.

Treatment of unresectable skull base meningiomas with somatostatin analogs

2011 ◽  
Vol 30 (5) ◽  
pp. E11 ◽  
Author(s):  
Chris Schulz ◽  
René Mathieu ◽  
Ulrich Kunz ◽  
Uwe Max Mauer
Keyword(s):  
Surgical Treatment ◽  
Mr Imaging ◽  
Skull Base ◽  
Somatostatin Analogs ◽  
Cranial Nerves ◽  
Insurance Company ◽  
Mr Images ◽  
Study Results ◽  
Skull Base Meningiomas ◽  
Tumor Enlargement

Object The standard surgical treatment for meningiomas is total resection, but the complete removal of skull base meningiomas can be difficult for several reasons. Thus, the management of certain meningiomas of the skull base—for example, those involving basal vessels and cranial nerves—remains a challenge. In recent reports it has been suggested that somatostatin (SST) administration can cause growth inhibition of unresectable and recurrent meningiomas. The application of SST and its analogs is not routinely integrated into standard treatment strategies for meningiomas, and clinical studies proving growth-inhibiting effects do not exist. The authors report on their experience using octreotide in patients with recurrent or unresectable meningiomas of the skull base. Methods Between January 1996 and December 2010, 13 patients harboring a progressive residual meningioma (as indicated by MR imaging criteria) following operative therapy were treated with a monthly injection of the SST analog octreotide (Sandostatin LAR [long-acting repeatable] 30 mg, Novartis). Eight of 13 patients had a meningioma of the skull base and were analyzed in the present study. Postoperative tumor enlargement was documented in all patients on MR images obtained before the initiation of SST therapy. All tumors were benign. No patient received radiation or chemotherapy before treatment with SST. The growth of residual tumor was monitored by MR imaging every 12 months. Results Three of the 8 patients had undergone surgical treatment once; 3, 2 times; and 2, 3 times. The mean time after the last meningioma operation (before starting SST treatment) and tumor enlargement as indicated by MR imaging criteria was 24 months. A total of 643 monthly cycles of Sandostatin LAR were administered. Five of the 8 patients were on SST continuously and stabilized disease was documented on MR images obtained in these patients during treatment (median 115 months, range 48–180 months). Three of the 8 patients interrupted treatment: after 60 months in 1 case because of tumor progression, after 36 months in 1 case because of side effects, and after 36 months in 1 case because the health insurance company denied cost absorption. Conclusions Although no case of tumor regression was detected on MR imaging, the study results indicated that SST analogs can arrest the progression of unresectable or recurrent benign meningiomas of the skull base in some patients. It remains to be determined whether a controlled prospective clinical trial would be useful.

Sign in / Sign up

Export Citation Format

Share Document